New Triple Therapy in Newly Diagnosed Type 2 Diabetes

Exclusion Criteria

• •1. Individuals with type 1 diabetes or special types of diabetes.
• •2. Allergy or intolerance to investigational drugs.
• •3. Estimated Glomerular Filtration Rate (eGFR) \<20 mL/min/1.73 m².
• •4. Individuals with heart failure in New York Heart Association \[NYHA\] class III or IV in the 6 months prior to randomization.
• •5. History of bladder cancer or hematuria.
• •6. History of Multiple Endocrine Neoplasia Type 2 (MEN 2) or relevant family history.
• •7. History or family history of Medullary Thyroid Carcinoma (MTC), or susceptibility to MTC due to hereditary conditions.
• •8. History of fasting blood glucose≥13.9 mmol/L or the necessity for insulin use due to severe infection, diabetic foot, etc.
• •9. History of acute diabetic complications: including diabetic ketoacidosis, hyperglycemic hyperosmolar state, lactic acidosis.
• •10. Severe diabetic microvascular complications: proliferative retinopathy, or urinary AER\>300mg/g, or urinary protein positive, quantitative \>0.5g/24h.
• •11. Uncontrolled painful diabetic neuropathy and significant diabetic autonomic neuropathy.
• •12. Severe diabetic macrovascular complications: myocardial infarction, stroke or hospitalization for unstable angina and/or transient ischemic attack and/or peripheral arterial disease required for vascular intervention or amputation within the 12 months prior to screening.
• •13. Blood pressure persistently higher than 180/110 mmHg and not controllable to ≤160/100 mmHg within 1 week.
• •14. Alanine Aminotransferase (ALT) ≥2.5 times the upper normal limit, total bilirubin ≥1.5 times the upper normal limit.
• •15. Hemoglobin \<100g/L or requiring regular blood transfusion.
• •16. Use of medicines potentially affecting blood glucose for more than 1 week cumulatively in the past 12 weeks, such as corticosteroids, growth hormone analogs, estrogen/progestogen, high-dose diuretics, antipsychotic drugs, etc.
• •17. Participation in another trial involving medicine therapy within the past 3 months.
• •18. Expected lifespan less than 2 years as per the investigator's clinical judgment, e.g., but not limited to malignancy.
• •19. Pregnant or lactating females, or females of childbearing potential who cannot or are unwilling to use adequate contraception.
• •20. Deemed unsuitable for participation in this clinical trial at the discretion of the investigator.